➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Merck
Dow
Johnson and Johnson
AstraZeneca

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for ASLAN001


Email this page to a colleague

« Back to Dashboard

What is the drug development status for ASLAN001?

ASLAN001 is an investigational drug.

There have been 11 clinical trials for ASLAN001. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2017.

The most common disease conditions in clinical trials are Biliary Tract Neoplasms, Stomach Neoplasms, and Neoplasms. The leading clinical trial sponsors are Aslan Pharmaceuticals, National University Hospital, Singapore, and National Medical Research Council (NMRC), Singapore.

There are one hundred and twenty-one US patents protecting this investigational drug and seven hundred and ninety-nine international patents.

Recent Clinical Trials for ASLAN001
TitleSponsorPhase
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract CancerAslan PharmaceuticalsPhase 2
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)Aslan PharmaceuticalsPhase 2/Phase 3
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract CancerAslan PharmaceuticalsPhase 2/Phase 3

See all ASLAN001 clinical trials

Clinical Trial Summary for ASLAN001

Top disease conditions for ASLAN001
Top clinical trial sponsors for ASLAN001

See all ASLAN001 clinical trials

US Patents for ASLAN001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASLAN001   Get Started Free Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer Capella Therapeutics, Inc. (San Diego, CA)   Get Started Free
ASLAN001   Get Started Free Methods for the treatment of HER2 amplified cancer Pharmacyclics LLC (Sunnyvale, CA)   Get Started Free
ASLAN001   Get Started Free Compositions of obeticholic acid and methods of use Intercept Pharmaceuticals, Inc. (New York, NY)   Get Started Free
ASLAN001   Get Started Free Androgen receptor antagonists The Regents of the University of California (Oakland, CA)   Get Started Free
ASLAN001   Get Started Free Gene fusions and gene variants associated with cancer LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA)   Get Started Free
ASLAN001   Get Started Free Anti-neurotensin antibodies and uses thereof INSERM (Institut National de la Sante et de la Recherche Medicale) (Paris, FR) Universite Paris Descartes (Paris, FR)   Get Started Free
ASLAN001   Get Started Free mTORC1 inhibitors The Regents of the University of California (Oakland, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ASLAN001

Drugname Country Document Number Estimated Expiration Related US Patent
ASLAN001 Australia AU2015231202 2034-03-20   Get Started Free
ASLAN001 Canada CA2943220 2034-03-20   Get Started Free
ASLAN001 China CN106536506 2034-03-20   Get Started Free
ASLAN001 European Patent Office EP3119762 2034-03-20   Get Started Free
ASLAN001 Israel IL247852 2034-03-20   Get Started Free
ASLAN001 Japan JP2017512833 2034-03-20   Get Started Free
ASLAN001 Japan JP2020007327 2034-03-20   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKinsey
Express Scripts
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.